NADPH oxidase inhibitors (GlaxoSmithKline)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameNADPH oxidase inhibitors (GlaxoSmithKline)
Drug Alias NameNOX2 inhibitors (GlaxoSmithKline)GSK-2795039GSK-2654261
ClassificationSmall molecules
Mechanisms of ActionNADPH oxidase inhibitorsNeuroprotectants
TargetsNADPH oxidase
Therapy Area/IndicationsNerve Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsNerve Degeneration

Other Information

ATC CodeN/A
Related LinksN/A